GK Wealth Management LLC Trims Position in DexCom, Inc. $DXCM

GK Wealth Management LLC decreased its stake in DexCom, Inc. (NASDAQ:DXCM) by 27.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,013 shares of the medical device company’s stock after selling 1,154 shares during the quarter. GK Wealth Management LLC’s holdings in DexCom were worth $263,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of DXCM. Brighton Jones LLC increased its position in DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after buying an additional 11,946 shares in the last quarter. Bank Pictet & Cie Europe AG increased its position in DexCom by 1.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company’s stock worth $8,637,000 after buying an additional 2,010 shares in the last quarter. Focus Partners Wealth purchased a new stake in shares of DexCom during the fourth quarter worth about $496,000. Quantinno Capital Management LP grew its position in shares of DexCom by 189.3% during the fourth quarter. Quantinno Capital Management LP now owns 65,289 shares of the medical device company’s stock worth $5,078,000 after purchasing an additional 42,718 shares in the last quarter. Finally, Snowden Capital Advisors LLC grew its position in shares of DexCom by 23.4% during the fourth quarter. Snowden Capital Advisors LLC now owns 8,170 shares of the medical device company’s stock worth $635,000 after purchasing an additional 1,548 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the subject of several research analyst reports. Mizuho increased their target price on DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 16th. Argus assumed coverage on DexCom in a research note on Thursday, August 21st. They set a “buy” rating and a $100.00 price target for the company. Morgan Stanley increased their price target on DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. The Goldman Sachs Group initiated coverage on DexCom in a research note on Friday, May 30th. They issued a “buy” rating and a $104.00 price objective for the company. Finally, Barclays raised their price objective on DexCom from $93.00 to $98.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 30th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average target price of $99.89.

DexCom Trading Up 0.3%

Shares of NASDAQ:DXCM opened at $76.22 on Monday. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25. The business’s fifty day simple moving average is $80.88 and its 200-day simple moving average is $78.58. The company has a market capitalization of $29.89 billion, a PE ratio of 52.93, a P/E/G ratio of 1.60 and a beta of 1.48. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period last year, the business posted $0.43 EPS. The business’s revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 1,466 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the sale, the executive vice president owned 105,223 shares of the company’s stock, valued at $8,417,840. This trade represents a 1.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kyle Malady sold 667 shares of the firm’s stock in a transaction on Friday, September 5th. The stock was sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the sale, the director directly owned 22,667 shares of the company’s stock, valued at $1,832,853.62. The trade was a 2.86% decrease in their position. The disclosure for this sale can be found here. Insiders sold 8,315 shares of company stock worth $689,431 over the last quarter. Company insiders own 0.32% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.